1. Home
  2. ORA vs RYTM Comparison

ORA vs RYTM Comparison

Compare ORA & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ORA
  • RYTM
  • Stock Information
  • Founded
  • ORA 1965
  • RYTM 2008
  • Country
  • ORA United States
  • RYTM United States
  • Employees
  • ORA N/A
  • RYTM N/A
  • Industry
  • ORA Electric Utilities: Central
  • RYTM Biotechnology: Pharmaceutical Preparations
  • Sector
  • ORA Utilities
  • RYTM Health Care
  • Exchange
  • ORA Nasdaq
  • RYTM Nasdaq
  • Market Cap
  • ORA 4.6B
  • RYTM 4.3B
  • IPO Year
  • ORA 2004
  • RYTM 2017
  • Fundamental
  • Price
  • ORA $84.21
  • RYTM $61.99
  • Analyst Decision
  • ORA Buy
  • RYTM Strong Buy
  • Analyst Count
  • ORA 7
  • RYTM 12
  • Target Price
  • ORA $84.43
  • RYTM $76.75
  • AVG Volume (30 Days)
  • ORA 443.9K
  • RYTM 525.0K
  • Earning Date
  • ORA 08-05-2025
  • RYTM 08-05-2025
  • Dividend Yield
  • ORA 0.57%
  • RYTM N/A
  • EPS Growth
  • ORA N/A
  • RYTM N/A
  • EPS
  • ORA 2.06
  • RYTM N/A
  • Revenue
  • ORA $885,250,000.00
  • RYTM $136,863,000.00
  • Revenue This Year
  • ORA $9.62
  • RYTM $37.56
  • Revenue Next Year
  • ORA $14.18
  • RYTM $74.99
  • P/E Ratio
  • ORA $40.80
  • RYTM N/A
  • Revenue Growth
  • ORA 1.95
  • RYTM 48.88
  • 52 Week Low
  • ORA $61.58
  • RYTM $39.46
  • 52 Week High
  • ORA $86.00
  • RYTM $69.89
  • Technical
  • Relative Strength Index (RSI)
  • ORA 75.26
  • RYTM 47.67
  • Support Level
  • ORA $79.20
  • RYTM $60.70
  • Resistance Level
  • ORA $80.18
  • RYTM $62.65
  • Average True Range (ATR)
  • ORA 1.65
  • RYTM 2.39
  • MACD
  • ORA 0.76
  • RYTM -0.52
  • Stochastic Oscillator
  • ORA 85.95
  • RYTM 14.04

About ORA Ormat Technologies Inc.

Ormat Technologies Inc is engaged in the geothermal and recovered energy power business. It is engaged in three business segments: Electricity Segment. where the company develops, builds, owns and operates geothermal, solar PV and recovered energy-based power plants in the United States and geothermal power plants in other countries and sell the electricity generated. Product Segment includes designing, manufacturing and selling equipment for geothermal and recovered energy-based electricity generation and providing services relating to the engineering, procurement and construction of geothermal and recovered energy-based power plants. Energy Storage Segment includes owning and operating grid-connected which provide capacity, energy and ancillary services directly to the electric grid.

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.

Share on Social Networks: